Treatment with indigo naturalis (IN) is effective in treating ulcerative colitis (UC) and inducing clinical response and mucosal healing, even in patients with steroid-dependent disease or anti–TNF-α refractoriness.
In patients with inflammatory bowel diseases (IBD) who underwent colonoscopic surveillance for colorectal neoplasia (CRN), indefinite dysplasia was independently associated with a significant increase in advanced CRN risk.
For both patients with ulcerative colitis and those with Crohn disease, psychiatric diagnoses were more common in those who were elderly (greater than 65 years old), women, and white, and those with psychiatric conditions more frequently had a history of alcohol abuse, tobacco and substance abuse, personality disorder, and corticosteroid use.
Researchers concluded that fecal tests like FCP do not appear to be affected by physiological changes that occur during pregnancy and that these tests may be useful in predicting IBD activity across all gestational periods, including conception.
Having a mother with a diagnosis of inflammatory bowel disease (IBD), being in the highest socioeconomic quintile at birth, and having an infection in the first year of life increases the risk of developing IBD.
In terms of benefit and risk, biologics were both considered more beneficial and riskier than immunomodulators. Bowel resection was considered to be slightly more risky, but more beneficial than biologic treatment.
Crohn disease and ulcerative colitis comprise the 2 primary subtypes of inflammatory bowel diseases (IBD). IBD currently has no known cure and whose pathogenesis is not well understood. However, an increasing amount of research points to genetic risk factors combined with antibiotic use and changes in intestinal microbiota as triggers for the onset of IBD.1,2…